UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 298

Sortiert nach

Mutations and prognosis in primary myelofibrosis

Leukemia, 2013-09, Vol.27 (9), p.1861-1869

2013

Link zum Volltext

Verfügbarkeit prüfen

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms

Leukemia, 2016-02, Vol.30 (2), p.431-438

2016

Link zum Volltext

Verfügbarkeit prüfen

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders

Leukemia, 2008-05, Vol.22 (5), p.905-914

2008

Link zum Volltext

Verfügbarkeit prüfen

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

Leukemia, 2015-11, Vol.29 (11), p.2126-2133

2015

Link zum Volltext

Verfügbarkeit prüfen

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

Leukemia, 2014-09, Vol.28 (9), p.1804-1810

2014

Link zum Volltext

Verfügbarkeit prüfen

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both

Leukemia, 2016-05, Vol.30 (5), p.1018-1024

2016

Link zum Volltext

Verfügbarkeit prüfen

Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib

Leukemia, 2014-02, Vol.28 (2), p.449-451

2014

Link zum Volltext

Verfügbarkeit prüfen

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment

Leukemia, 2008-02, Vol.22 (2), p.437-438

2008

Link zum Volltext

Verfügbarkeit prüfen

Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making

Leukemia, 2013-05, Vol.27 (5), p.997-999

2013

Link zum Volltext

Verfügbarkeit prüfen

JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy

Leukemia, 2016-08, Vol.30 (8), p.1772-1775

2016

Link zum Volltext

Verfügbarkeit prüfen

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

Leukemia, 2017-04, Vol.31 (4), p.896-902

2017

Link zum Volltext

Verfügbarkeit prüfen

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations

Leukemia, 2017-04, Vol.31 (4), p.882-888

2017

Link zum Volltext

Verfügbarkeit prüfen

How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis?

Leukemia, 2016-07, Vol.30 (7), p.1453-1455

2016

Link zum Volltext

Verfügbarkeit prüfen

Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups

Haematologica (Roma), 2013-09, Vol.98 (9), p.1344-1352

2013

Link zum Volltext

Verfügbarkeit prüfen

Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis

Leukemia, 2013-10, Vol.27 (10), p.2084-2086

2013

Link zum Volltext

Verfügbarkeit prüfen

Strategies for dissemination and implementation of guidelines

Neurological sciences, 2006-06, Vol.27 Suppl 3 (S3), p.S231-s234

Barosi, G

2006

Link zum Volltext

Verfügbarkeit prüfen

Reply to Passamonti et al: ruxolitinib and survival improvement in patients with myelofibrosis

Leukemia, 2015-03, Vol.29 (3), p.740-740

2015

Link zum Volltext

Verfügbarkeit prüfen

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis

Leukemia, 2015-05, Vol.29 (5), p.1209-1210

2015

Link zum Volltext

Verfügbarkeit prüfen

Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?

Leukemia, 2014-11, Vol.28 (11), p.2267-2270

2014

Link zum Volltext

Verfügbarkeit prüfen

SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias

Annals of oncology, 2014-12, Vol.25 (12), p.2339-2350

2014

Link zum Volltext

Verfügbarkeit prüfen

Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type

Bone marrow transplantation (Basingstoke), 2010-03, Vol.45 (3), p.458-463

2010

Link zum Volltext

Verfügbarkeit prüfen

Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines

Leukemia research, 2010-12, Vol.34 (12), p.1576-1588

2010

Link zum Volltext

Verfügbarkeit prüfen

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

Leukemia, 2017-05, Vol.31 (5), p.1252-1252

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 298

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(270)
Mit Volltextzugriff
(200)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(201)
Science & Technology
(175)
Life Sciences & Biomedicine
(163)
Hematology
(129)
Male
(102)
Biological And Medical Sciences
(96)
Female
(96)
Medical Sciences
(94)
Middle Aged
(90)
Adult
(87)
Aged
(72)
Hematologic And Hematopoietic Diseases
(55)
Oncology
(50)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(38)
Adolescent
(35)
Myelofibrosis
(28)
Erythropoiesis
(27)
Child
(23)
Primary Myelofibrosis - Complications
(22)
Prognosis
(22)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mutations and prognosis in primary myelofibrosis

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both

Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment

Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making

JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations

How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis?

Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group

Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups

Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis

Strategies for dissemination and implementation of guidelines

Reply to Passamonti et al: ruxolitinib and survival improvement in patients with myelofibrosis

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis

Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?

SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias

Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type

Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

Suchergebnisse filtern